



Bringing the best of
cannabis to better the lives
of people and animals

Investor Presentation

Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso.

This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision.

The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

To the maximum extent permitted by law, Creso, its related bodies corporate and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including (but not limited to) any liability arising under the Australian Securities and Investments Commission Act 2001, Corporation Act 2001 or from the fault or negligence on the part of any person, for any loss arising from the use of the presentation or its contents arising in connection with it. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.

Investment Highlights



Fills void in current market with growing need for **trusted products** that meet the highest global pharmaceutical standards



Revenues from animal and human product launches in Switzerland and selected EU countries in 2018



Growing market opportunity with a **number of products in pipeline** targeting human and animal nutraceutical markets



Exclusive licensing deals that gives Creso access to unique drug delivery IP and substantial distribution globally



Diversified revenue stream targeting human and animal health markets. More countries liberalizing medicinal cannabis



Access to the **global market** at the start of its growth. Increasing scientific evidence on efficacy of cannabis-based treatments



Company well placed to be the **"gold standard"** in cannabis and hemp derived therapeutics, nutraceuticals and lifestyle products



Company Overview

Creso Pharma brings pharmaceutical expertise and methodological rigor to the world of medicinal cannabis and strives for the highest quality in its products

MISSION:
Bringing the best of cannabis to better the lives of people and animals

Creso Pharma develops cannabis- and hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health

CRESO PHARMA LTD

Company Overview

BUSINESS DESCRIPTION

- A global medicinal cannabis innovator founded by a team of executives incorporating pharmaceutical product development and GMP expertise
- Founded in 2015 and ASX listed on 20 October 2016 (CPH.ASX)
- R&D and marketing in Switzerland, establishing cultivation in Canada, Colombia and Israel
- Innovative products for humans and animals already launched in certain European markets
- Path to revenue expedited through strategic IP and highly reputable distribution partnerships
- First to import medicinal cannabis into Australia

FINANCIAL SNAPSHOT¹


	AUD
Share Price	\$0.70
52 Week High/Low	\$1.65/\$0.42
Shares on Issue	109.5
Market Capitalization	\$76.7
Total Debt Outstanding	Nil
Cash	\$7.2
Enterprise Value	\$69.5
LTM Revenue	\$0.50
LTM EBITDA	(\$2.2)
LTM Earnings Per Share	(\$0.02)

SHARE PRICE CHART¹



OWNERSHIP STRUCTURE¹

Top 20 Shareholders	41.27%
Top 5 Shareholders	
HSBC Custody Nominees (Australia) Ltd	8.12%
Miriam Halperin Wernli	7.53%
International Water Energy Savers Ltd	6.21%
Anglo Australasia Holdings Pty Ltd	3.65%
Ross Smith	2.51%



¹ Market data taken as at 30 June 2018 unless specified otherwise. All figures in millions except per share data.

Medicinal Significance of Cannabis and Hemp



MARKET SIZE

- The Cannabis market is growing rapidly
- Medicinal Cannabis worldwide will reach up to \$31 billion¹ dollars in sales over the next four years



EVIDENCE

- More than 10,000 studies on Cannabis treatments, US National Academy of Sciences and World Health Organization² have found evidence for effectiveness of Cannabis and Hemp derivatives in a variety of health conditions



COMPOUND RICH

- The cannabis plant consists of over 460 compounds
- At least 80 are active compounds (Cannabinoids)
- Creso focuses on **full spectrum plant extracts**
- Cannabinoids and other compounds have a greater effect when taken together than when separated into individual single compounds - potentially resulting in a **synergetic entourage effect**³

HISTORICALLY PROVEN

- Long history of medicinal use dating back thousands of years




¹ Brightfield Report


² National Academies of Sciences, Engineering, and Medicine, 2017, WHO 39th ECDD, 2017

³ Mechoulam, 1999, Ulrich-Merzenich, 2010, Rosenfeld, 2011, Gallily 2015

Geographically Diversified and Vertically Integrated Company



Key Achievements



The Creso Team



Dr. Miri Halperin-Wernli | CEO & Co-Founder

- 25+ years of strategic and operational leadership in global pharmaceutical and biomedical industries in Switzerland and in the US

Boaz Wachtel | Non-Executive, Chairman & Co-Founder

- Leading medical cannabis expert, co-founder and former MD of Phytotech Medical

Adam Blumenthal | Non-Executive Director & Co-Founder

- 10+ years experience in investment banking and corporate finance. Provided capital raising and financing solutions to an extensive number of listed and unlisted companies

Dr. James Ellingford | Non-Executive Director

- Vast experience in the international arena, successfully developing close ties with both financial institutions and Government throughout the world



Chris Grundy | Chief Financial Officer

John Griese | Chief Operating Officer, Americas

Amit Edri | International Business Development

Dr Norman Nashed | Director, Global Operations

Chris Hession | Director of Strategic Partnerships

Dr. Stu Fillman | Director, Medical APAC

Bill Fleming | Managing Director, Mernova

Charles Williams | Quality Assurance, Mernova

Dr Gian Trepp | Director, Commercial & Marketing

Jorge Wernli | Director, Commercial & Market Access



Dr Raquel Peyraube | Industry Advisor

Prof Dr Felix Gutzwiller | Industry Advisor

Dr Isaac Kobrin | Industry Advisor




Dr Stephane Redey | Industry Advisor

Dr Demian Halperin | Medical Advisor Human

Dr Fabian Huwiler | Veterinary Advisor

Corporate Structure



CRESO PHARMA LIMITED (ASX:CPH)

Joint Ventures

CLV FRONTIER BRANDS

JV between Creso Pharma (33.3%), Baltic Beer Co (33.3%) and LGC Capital (33.3%)

Alcoholic & non-alcoholic cannabis derived beverages

ISRAEL


JV between Creso Pharma (74%) and Cohen Propagation Nurseries Ltd (26%)

Medicinal Cannabis

Creso Business Model

With an unparalleled track record of success commercializing a wide range of pharmaceutical and therapeutic solutions

WE COMBINE




Cultivation, Extraction & Purification Expertise

Cannabis & Hemp Derivatives:

- Full spectrum extracts
- Active API
- API

Global Footprint

Switzerland / Canada / Israel / Colombia



Partnerships with Commercial Market Leaders

Technology & Manufacturing

- Topical
- Buccal
- Water Solubles
- Other Technologies

Global Partners

- Domaco
- iNNutri
- Baltic Beer Company
- Felchlin Chocolatiers
- FRIKE Technologies
- Others to be Announced

WE APPLY



Purposeful Innovation

Pharmaceutical Rigor

This is how we do it:



Leveraging our cannabis & hemp product & applications expertise



Combining proprietary, in-house ingredients with third party technological know-how



Delivering products which meet and exceed customer expectations



WE CREATE



THERAPEUTICS



NUTRACEUTICALS



ANIMAL HEALTH



LIFESTYLE



TOPICALS

WE DELIVER

Global Consumer Access



Creso branded Products

Channel Partners


- Virbac, CH
- Doetsch Grether AG, CH
- Precision Healthcare, UK
- Mediphos OTC, Benelux
- Health House International, AUS
- Baltic Beer Company, UK
- Others to be Announced

A stylized graphic of a plant with several leaves. The left side of the image is a solid green vertical bar. The leaves on the left are filled with this green color. The leaves on the right are outlined in a light gray color against a dark gray background. The text 'Global Cultivation' is centered over the right side of the leaf graphic.

Global Cultivation

CRESO PHARMA LTD

Canada Mernova Medical Inc.



- Only Australian cannabis company building production capacity in Canada
- Direct access to the world's largest legal market for cannabis, projected to surpass C\$8-9bn in sales by 2024¹
- 20,000 sq. ft. facility providing ample initial production capacity 2m–4m grams cannabis annually; scalable to 200,000 sq. ft.
- Future build of GMP compliant CO2 extraction facility. High quality extracts for sale and product development
- Fully funded acquisition; facility construction financed with cash on hand
- Build completion expected Q3 2018 and first sales expected Q1 2019



Mernova Facility | as at July 2018

CRESO PHARMA LTD

Colombia

Kunna S.A.S.




- Acquisition of Kunna Canada Ltd¹ and its Colombian subsidiary, Kunna S.A.S. makes Creso the only Australian-listed medicinal cannabis company with direct exposure to the Colombian market
- Establishes Creso in the strategically important Latin American market, including Argentina, Colombia, Chile, Mexico and Uruguay
- Colombian market is growing strongly; cannabis consumption increased 15% p.a. between 2008 & 2013; US\$86.3mn spent on cannabis in 2008
- Columbia is expected to export more than 40.5 tonnes of medicinal cannabis oil by 2019
- Granting of a cultivation licence to Kunna in June 2018 gives Creso a significant competitive advantage



Kunna S.A.S | Current Operation

Israel JV with Cohen Propagation Nurseries Ltd



- First of its kind strategic partnership in the cultivation of medicinal cannabis
- Cohen is one of the most experienced agriculture companies in Israel, established in 1958. 550 highly trained staff work 15.7 hectares of greenhouses
- Cohen's products are famous for high quality, sterility and hygiene and are supplied with a special quality certificate from Israel's Ministry of Agriculture Plant Protection and Inspection Services
- The JV will develop an IMC-GAP¹ cultivation facility operating out of Cohen's existing greenhouse facilities



Cohen Propagation Nurseries Ltd | Gderot Operation

The background features a vertical split: the left side is a solid green color, and the right side is a dark grey color. Overlaid on this background are stylized leaf patterns. On the green side, there are several overlapping leaf outlines in a lighter shade of green. On the grey side, there are several overlapping leaf outlines in a light grey color. The text is centered in the grey area.

Products & Product Pipeline

A Portfolio Approach



The medicinal cannabis industry is in its infancy and is driven by challenging regulatory policies for access and compliance

The global nutraceuticals industry now exceeds US\$200bn in sales¹ and continues to grow at a significant pace. Products such as cannaQIX® demonstrate that, with the right knowledge, cannabis and hemp can be used to great consumer benefit in this sector

CBD from the hemp plant is just as effective in animals as in humans due to the shared endocannabinoid system. There exists a significant need for nutraceutical products targeting animal stress, anxiety and age related ailments

From the nutritional benefits of hemp seeds to a world of new and unique flavoring systems possible from cannabis terpenes, a whole world of enhanced food and beverage products from beer to chocolates is possible

Topically applied CBD in analgesics and skin care leverages the body's endocannabinoid system to improve skin health and appearance and deal with muscle injuries, arthritis and osteoarthritis without the use of harsh chemicals



¹ Source: KPMG report (Nutraceuticals: The Future of Intelligent Food) - <https://home.kpmg.com/content/dam/kpmg/pdf/2015/05/nutraceuticals-the-future-of-intelligent-food.pdf>



Therapeutics cannaQIX® 50 – Medicinal Cannabis



Medicinal Cannabis (MC) worldwide market opportunity \$31 billion¹ dollars over 4 years



cannaQIX® 50 is CBD based full spectrum hemp extract MC product in innovative, non-oil based, buccal lozenge formulation with vitamins, minerals and capsiicum to assist with managing pain



Will be launched first in New Zealand in Q3 2018, followed by Australia in 2019 with ongoing discussions in European countries where MC has been legalized



Nutraceuticals

cannaQIX®10 and cannaDOL®- Food Supplement



Global Supplements Market worth \$198.7bn in 2016 and will increase to \$285bn by 2021¹
CAGR of 7.5%¹



cannaQIX®10 is a sugar free non-euphoric Food Supplement in innovative buccal formulation containing CBD from full spectrum hemp oil extract, vitamins, minerals and capsicum used OTC (without prescription) Targets stress reduction and support of mental and nervous functions in humans

cannaDOL® Oral formulation is a food supplement, combining CBD with vitamins and minerals and a proprietary delivery technology, to support collagen synthesis, reduce fatigue and stimulate metabolism



cannaQIX®10 Launched in Switzerland & Liechtenstein with market introductions in the UK, the Netherlands, Belgium and Luxemburg planned for 2018 alongside formal conformity as a food supplement; cannaDOL® is planned to launch in 2019



Animal Health anibidiol®



CRESO
ANIMAL HEALTH



US pet dietary supplement market worth over \$500m¹
CAGR of 5%¹



anibidiol® is a complementary feed for companion animals with CBD from full spectrum hemp oil extract in an innovative granular buccal formulation

CBD from hemp is effective in animals as well as humans due to the shared endocannabinoid system



Launched in Switzerland & Liechtenstein in November 2017 with Virbac, leader in global animal health. Further European market introductions in late discussions

Additional life cycle products to expand anibidiol® range to be launched Q3/Q4 2018






Cannabis derived Beverages



Projected sales in Canada alone are over \$160 million dollars of the alcoholic beverage sector¹



CLV Frontiers in Tallinn, Estonia is working on a portfolio of cannabis and hemp-derived alcoholic and non alcoholic beverages containing unique terpene mixes

The terpenes in the beer will carry the characteristic odour, fragrance and taste of cannabis but will not contain THC or CBD or any other cannabinoids



Launch and first commercial sales are expected to be in Q3 2018

Swiss Chocolates

In California 10% of total cannabis sales were edibles, over \$180 million in product²

Creso's range of unique, ultra-premium Swiss-made chocolate products containing various cannabis terpenes mixes

Launch discussions ongoing with commercial partners in Canada, Australia and Israel

What is a Terpene?

Cannabis terpenes are fragrant oils that give cannabis its aromatic diversity and signature. These oils are secreted in the flower's sticky resin glands, the same ones that produce THC, CBD, and other cannabinoids.



¹ Anderson Economic Group, a business consulting firm in New York
² Arcview market research



cannaDOL® – Analgesics



Market in Europe for oral and topical analgesics is €3.5 billion. Analgesics sales in 2016 were €603 million in the UK and €203 million in Switzerland¹




Creso has partnered with Frike Technologies (largest independent Swiss manufacturing group) to develop the cannaDOL® range of organic CBD-based functional topicals


These will address the analgesic need in sports-related muscle injuries, arthritis and osteoarthritis, and be registered as appropriate in jurisdictions beginning with Cosmetics in the European Union



The cannaDOL® product range will be launched with commercial partners in Q4 2018



Product Pipeline and Brands



A stylized graphic of a plant with several leaves. The left side of the image is a solid green background, and the right side is a dark gray background. The leaves are outlined in a lighter green on the left and a lighter gray on the right, creating a symmetrical effect across a vertical line.

Contact Us

Creso Pharma Ltd

T: +61 2 8067 8606

E: info@cresopharma.com

W: www.cresopharma.com

A: Level 24, 300 Barangaroo Avenue Barangaroo NSW 2000 Australia

Australia

EverBlu Capital

T: +61 2 8249 0000

E: info@everblucapital.com

W: www.everblucapital.com

A: Level 39, 88 Phillip Street, Sydney NSW 2000

Frankfurt

DGWA

T: +49 69 247 471 047

E: info@dgwa.org

W: <https://dgwa.org/>

A: Kaiserhofstraße 13, 60313 Frankfurt am Main